The key finding
A 2024 review highlights that transjugular renal biopsy (TJRB) offers a safe alternative to the standard percutaneous approach for diagnosing kidney diseases in patients at high risk of bleeding. While percutaneous biopsy—inserting a needle through the skin directly into the kidney—works well for most patients, approximately 5-10% face elevated risks from this standard approach. For these individuals, TJRB provides comparable diagnostic value by accessing the kidney through neck veins rather than through the back, yet physicians may not be utilizing this technique as often as appropriate.
What the study looked like
This review article examined the current evidence on transjugular renal biopsy as an alternative diagnostic approach. Rather than conducting new experiments, the authors synthesized existing literature on TJRB techniques, safety profiles, and outcomes. The review focused on patients who require kidney tissue diagnosis but face contraindications to percutaneous biopsy—particularly those with clotting disorders, severe obesity, uncontrolled high blood pressure, or only one functioning kidney. The authors analyzed procedural techniques, complication rates, and the learning curve required for physicians to perform TJRB competently. According to the evidence reviewed, physicians typically need approximately 10 cases to become proficient in this technically demanding procedure, which involves navigating a catheter from the jugular vein in the neck down to the renal vein to obtain kidney tissue samples.
Why researchers think this happened
The authors suggest TJRB remains underutilized despite its benefits because of several factors. The procedure requires specialized interventional radiology skills and equipment not universally available at all medical centers. The learning curve—steeper than for percutaneous biopsy—may discourage adoption, as physicians need dedicated training and practice to master the technique. Additionally, the traditional percutaneous approach has been the standard for decades, creating institutional inertia. However, for high-risk patients, the transjugular route offers a crucial advantage: by accessing the kidney through the venous system rather than puncturing through the back, it significantly reduces bleeding complications. The neck access point also allows for immediate pressure application if bleeding occurs, unlike internal kidney bleeding from percutaneous approaches. Prior research has demonstrated that when kidney failure or bleeding disorders make standard biopsy dangerous, TJRB provides diagnostic tissue while minimizing these specific risks.
How to read this carefully
This review has important limitations readers should consider. As a review article rather than an original study, it synthesizes existing evidence without presenting new patient data or comparative trials. The authors don’t provide specific complication rate statistics comparing TJRB to percutaneous approaches across large populations, making it difficult to quantify the precise risk-benefit tradeoff. The 10-case learning curve mentioned represents an approximation rather than data from rigorous training studies. Additionally, the review doesn’t address which specific patient populations benefit most from TJRB or provide clear decision-making algorithms for choosing between approaches. The underutilization claim isn’t supported with hard data on how often eligible patients actually receive TJRB versus being denied biopsy altogether, leaving the extent of the problem unclear.
What this means for everyday life
If you or a family member faces kidney disease requiring tissue diagnosis but has bleeding disorders, takes blood thinners, or has other conditions making standard biopsy risky, it’s worth asking your nephrologist whether transjugular biopsy might be an option. Not all hospitals offer this specialized procedure, so you may need referral to a center with interventional radiologists trained in the technique. Given this evidence, patients previously told they couldn’t safely undergo kidney biopsy might now have access to diagnosis that seemed too dangerous before. Understanding that alternative biopsy routes exist can empower conversations with medical teams about balancing diagnostic needs against procedural risks—though the final decision requires careful discussion of your individual circumstances with qualified specialists who can assess whether the benefits outweigh the complexity of this approach.